INDIVIOR PLC/S (OTCMKTS:INVVY) announced its earnings results on Thursday. The company reported ($0.25) EPS for the quarter, reports. INDIVIOR PLC/S had a net margin of 17.07% and a return on equity of 132.33%. The business had revenue of $133.00 million for the quarter. INDIVIOR PLC/S updated its FY 2020
Pre-Market guidance to EPS.

OTCMKTS:INVVY opened at $2.85 on Friday. The company has a fifty day moving average of $2.59 and a 200-day moving average of $2.95. The firm has a market capitalization of $434.07 million, a P/E ratio of 2.59 and a beta of -0.20. INDIVIOR PLC/S has a twelve month low of $1.98 and a twelve month high of $7.74.

Separately, Zacks Investment Research downgraded INDIVIOR PLC/S from a “buy” rating to a “hold” rating in a report on Wednesday.

INDIVIOR PLC/S Company Profile

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.

Further Reading: How prevalent are 12b-1 fees?


Receive News & Ratings for INDIVIOR PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INDIVIOR PLC/S and related companies with's FREE daily email newsletter.